Caris Life Sciences, Inc. (NASDAQ:CAI) Stock Has Average Target Price of $31.18

Caris Life Sciences, Inc. (NASDAQ:CAI) has received an average rating of “Moderate Buy” from the fourteen analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $31.18.

A number of equities analysts have commented on the company. Wall Street Zen raised Caris Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Piper Sandler lifted their price target on Caris Life Sciences from $22.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday. Weiss Ratings upgraded Caris Life Sciences from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday. UBS Group set a $38.00 price target on Caris Life Sciences in a research report on Thursday, November 5th. Finally, Canaccord Genuity Group increased their price objective on Caris Life Sciences from $22.00 to $30.00 and gave the company a “hold” rating in a research note on Monday, October 19th.

Insiders Place Their Bets

In other news, insider John Russel Denton sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $31.82, for a total transaction of $238,650.00. Following the completion of the sale, the insider owned 174,855 shares of the company’s stock, valued at $5,563,886.10. This represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brian Brille sold 400,000 shares of the stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $30.33, for a total transaction of $12,132,000.00. Following the completion of the sale, the insider owned 230,303 shares of the company’s stock, valued at $6,985,089.99. This trade represents a 63.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,004,712 shares of company stock valued at $27,205,419 in the last 90 days. 50.00% of the stock is owned by insiders.

Institutional Trading of Caris Life Sciences

Several large investors have recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in Caris Life Sciences by 133.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,263 shares of the company’s stock valued at $39,000 after acquiring an additional 721 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Caris Life Sciences by 839.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock worth $29,000 after purchasing an additional 1,469 shares during the last quarter. Fifth Third Bancorp purchased a new stake in shares of Caris Life Sciences in the first quarter valued at approximately $31,000. Root Financial Partners LLC purchased a new stake in shares of Caris Life Sciences in the third quarter valued at approximately $60,000. Finally, MCF Advisors LLC acquired a new stake in shares of Caris Life Sciences in the second quarter valued at approximately $36,000.

Caris Life Sciences Stock Up 0.2%

CAI opened at $24.49 on Thursday. The company has a market cap of $7.02 billion, a PE ratio of 74.21, a price-to-earnings-growth ratio of 7.77 and a beta of 0.71. Caris Life Sciences has a twelve month low of $14.19 and a twelve month high of $36.50. The company has a 50-day moving average price of $29.45 and a 200 day moving average price of $21.73. The company has a quick ratio of 5.84, a current ratio of 6.71 and a debt-to-equity ratio of 0.61.

Caris Life Sciences (NASDAQ:CAI) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.02. Caris Life Sciences had a return on equity of 16.00% and a net margin of 9.16%. The company had revenue of $275.36 million for the quarter. During the same quarter in the previous year, the firm posted $0.08 earnings per share. The company’s quarterly revenue was up 27.0% on a year-over-year basis. Sell-side analysts expect that Caris Life Sciences will post 0.11 earnings per share for the current fiscal year.

About Caris Life Sciences

Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care. The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.